Electromed, Inc. (ELMD) Stock Price & Analysis
Electromed, Inc. (ELMD) rose 1.41% to USD 28 as of September 8, 2026 at 10:50 UTC, according to Nexqual real-time market data.
ELMD last closed at USD 27.61; the session ranged USD 27.2–28.14 on volume of 118,106 shares. Market capitalization is $234.25M, with a 52-week range of USD 23.01–47.4 (ASE). Source: Nexqual, September 8, 2026 at 10:50 UTC.
Key Statistics (as of September 8, 2026 at 10:50 UTC)
| Price | USD 28 |
|---|---|
| Change | ▲ 1.41% (up) |
| Previous Close | USD 27.61 |
| Open | USD 27.43 |
| Day Range | USD 27.2 – 28.14 |
| 52-Week Range | USD 23.01 – 47.4 |
| Volume | 118,106 shares |
| Market Cap | $234.25M |
| Exchange | ASE |
Technical Analysis (ELMD)
Nexqual's technical model rates ELMD "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 10:50 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.73 (oversold) |
| vs SMA50 | Below (USD 39.83) |
| MACD | -3.64 (negative) |
Analyst Ratings (ELMD)
Wall Street analysts rate ELMD "Strong Buy" based on 2 analysts, with a mean price target of USD 48.5 (range USD 47–50), per Nexqual as of September 8, 2026 at 10:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 48.5 |
| High Target | USD 50 |
| Low Target | USD 47 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ELMD)
| Next Earnings Date | 2026-11-11 |
|---|---|
| Revenue Estimate | $18.85M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.39 vs est 0.32 ▲ beat |
| 2025-12-31 | USD 0.32 vs est 0.26 ▲ beat |
| 2025-09-30 | USD 0.25 vs est 0.21 ▲ beat |
Source: Nexqual, September 8, 2026 at 10:50 UTC.
Financials & Fundamentals (ELMD)
| Total Revenue | $73.78M |
|---|---|
| Revenue Growth (YoY) | +11.60% |
| Gross Margin | +78.54% |
| Operating Margin | +19.70% |
| Profit Margin | +15.32% |
| ROE | +23.26% |
| Debt / Equity | 0.25 |
| Current Ratio | 4.69 |
| Total Cash | $20.45M |
| Total Debt | $133,000 |
| Free Cash Flow | $5.81M |
Source: Nexqual, September 8, 2026 at 10:50 UTC.
Financial Health Score (ELMD)
Nexqual rates Electromed, Inc.'s overall financial health "Strong" across five dimensions, as of September 8, 2026 at 10:50 UTC.
| Growth | Strong — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 79%, operating 20% |
| Balance Sheet | Strong — $20M cash, no debt |
| Cash Flow | Solid — FCF $6M, 8% margin |
| Efficiency | Strong — ROE 23%, ROA 14.5% |
Ownership (ELMD)
| Insider Ownership | +17.01% |
|---|---|
| Institutional Ownership | +60.47% |
| Shares Outstanding | 8.37M |
| Float | 6.93M |
| Short % of Float | +2.45% |
Source: Nexqual, September 8, 2026 at 10:50 UTC.
Leadership (ELMD)
Electromed, Inc. is led by James L. Cunniff (age 59), President, CEO & Director, per Nexqual as of September 8, 2026 at 10:50 UTC.
| President, CEO & Director | James L. Cunniff (age 59) |
|---|---|
| CFO, Treasurer & Secretary | Bradley M. Nagel (age 43) |
Major Backers & Investors (ELMD)
Notable institutional backers of Electromed, Inc. include J.e. Simmons & Co., P.c., Acadian Asset Management. LLC, Punch & Associates Investment Management, Inc., according to Nexqual as of September 8, 2026 at 10:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| J.e. Simmons & Co., P.c. | 5.78% |
| Acadian Asset Management. LLC | 2.65% |
| Punch & Associates Investment Management, Inc. | 2.61% |
| Two Sigma Investments, LP | 2% |
| Hunter Associates Investment Management LLC | 1.86% |
| Gamco Investors, Inc ET AL | 1.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.36% |
| Vanguard Group | 7.16% |
| Geode Capital | 2.6% |
| Dimensional Fund Advisors | 2.16% |
Source: Nexqual, September 8, 2026 at 10:50 UTC.
From Electromed, Inc.'s Latest SEC 10-K Filing (filed 2026-08-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.
- It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting.
- The company markets its products to physicians, health care providers, and directly to patients.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INFU | InfuSystems Holdings, Inc. | USD 12.24 | ▲ 0.82% |
| PDEX | Pro-Dex, Inc. | USD 73.41 | ▲ 17.31% |
| DLHC | DLH Holdings Corp. | USD 4.07 | ▼ 5.79% |
| IRMD | iRadimed Corporation | USD 83.45 | ▼ 3.16% |
| KRMD | KORU Medical Systems, Inc. | USD 3.25 | ▼ 1.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:50 UTC. This page is informational and not investment advice.